Shanghai Pharma's Cloud Health Subsidiary Acquires 51% Stake in Beijing Keyuan Pharmacy for RMB 49.54 Million

Recently, according to public information, Shanghai Pharma Health Commerce Co., Ltd. (hereinafter referred to as “SPH Health Commerce”) acquired Beijing Xinhai Keyuan Pharmacy Co., Ltd. (hereinafter referred to as “Keyuan Pharmacy”) implemented a unilateral capital increase and share expansion, acquiring a 51% equity stake and becoming the controlling shareholder.

This transaction also altered the equity structure of Beijing Xinhai Keyuan Pharmacy. Prior to the transaction, Beijing Keyuan Xinhai Pharmaceutical Trading Co., Ltd. held 100% of the equity in Beijing Xinhai Keyuan Pharmacy and exercised sole control over the company. Upon completion of the transaction, the equity structure was revised such that SPH Health Commerce holds 51% and Beijing Keyuan holds 49%, with both parties exercising joint control over the target company.

Beijing Xinhai Keyuan Pharmacy Co., Ltd. was established on March 22, 2002. It is a wholly foreign-owned enterprise (legal person sole proprietorship) wholly held by Beijing Keyuan Xinhai Pharmaceutical Operation Co., Ltd., which in turn is a wholly-owned subsidiary of Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. According to Shanghai Pharma’s 2025 announcement on guarantee quotas, all companies under the Keyuan Xinhai system are wholly-owned subsidiaries of Shanghai Pharma.

This indicates that the “Keyuan Group” had long been integrated into Shanghai Pharma’s commercial landscape, although it previously primarily fulfilled pharmaceutical distribution and supply chain functions. Keyuan Pharmacy, as a retail terminal in the Beijing region, holds substantial value.

First, Beijing, where Keyuan Pharmacy is located, represents the pinnacle of China’s pharmaceutical market. It concentrates the nation’s highest-quality medical resources, innovative drug approval capabilities, and patient populations with high payment capacity, making it a critical battleground for DTP (Direct-to-Patient) pharmacy operations. Second, leveraging Sinopharm Xinhai’s years of accumulated hospital channel relationships, government affairs expertise, and partnerships with pharmaceutical companies, Keyuan Pharmacy possesses the potential to rapidly transform into a professional service platform.

Finally, as a state-owned enterprise with local government backing, it enjoys policy advantages in areas such as health insurance integration and store site selection. The introduction of SPH Health Commerce as a strategic shareholder essentially entails professionally and digitally refining this unpolished gem, upgrading it into the flagship of the Group’s new retail strategy in the northern market.

On the other hand, SPH Health Commerce is not an ordinary pharmaceutical retailer. Established in Shanghai in 2015, it is an “Internet+” pharmaceutical commercial technology platform incubated and continuously supported by Shanghai Pharma. It provides lifecycle services for innovative drugs based on a professional pharmacy network, as well as “Internet+” services for general and chronic disease medications based on electronic prescriptions and cloud pharmacies.

According to Shanghai Pharma’s 2025 semi-annual report, SPH Health Commerce is leveraging the Group’s integrated wholesale and retail advantages to accelerate the deployment of hospital-adjacent pharmacies and specialized pharmacies (DTP pharmacies), rapidly emerging as a key channel for the initial launch of innovative drugs.

According to the official website of SPH Health Commerce, the company currently operates over 200 integrated professional pharmacies nationwide, covering 66 cities across 25 provinces. It boasts a team of more than 400 professional pharmacists, with specialized pharmaceutical services spanning 12 medical specialties and over 130 major disease types. The company achieves annual sales exceeding RMB 3 billion, connecting with 40+ internet hospitals affiliated with public hospitals and 260+ medical institutions; it collaborates with 10+ commercial insurance companies; and serves 300+ multinational and domestic pharmaceutical enterprises, achieving a 90% coverage rate for innovative drugs.

In summary, the acquisition of Keyuan Pharmacy represents a significant step for Shanghai Pharma Group in replicating this model across regions, expanding from East China to North China.

Notably, in addition to the “SPH New Retail Integration Strategy,” Shanghai Pharma Group is also continuously advancing the transformation and upgrading of SPH Sales Company in terms of marketing transformation. It is optimizing the specialized allocation of core business functions across various business units, commercial operations, and business development. Meanwhile, the Group has specifically emphasized strengthening its strategic layout in “Grand Health OTC + New Retail” and exploring new business models.

Therefore, this acquisition can be regarded as a concrete manifestation of this strategy. On the one hand, Beijing Xinhai Keyuan Pharmacy serves as an important channel and network in Beijing for Shanghai Pharma’s key products (such as major brands in the gastrointestinal and cardiovascular/cerebrovascular fields). On the other hand, Shanghai Pharma can leverage this merger to integrate the distribution network of Keyuan Xinhai, further reducing intermediate links and improving gross profit margins.

It is worth noting that, against the backdrop of the normalization of centralized volume-based procurement (VBP), consolidation among major pharmaceutical giants has become particularly crucial. By securing control over terminal channels to safeguard market share for industrial products, and by leveraging exclusive resources in industrial product portfolios to enhance the competitiveness of retail terminals, a mutually reinforcing cycle of dual empowerment is formed.

Meanwhile, pharmaceutical giants’ presence in China’s pharmaceutical distribution market has entered a new phase.

In recent years, China’s pharmaceutical giants, particularly the “national team,” have been rapidly expanding their nationwide footprint by leveraging their distinctive competitive advantages. As early as 2023, Shanghai Pharma Holdings and Shanghai Pharma Keyuan, subsidiaries under the commercial segment of Shanghai Pharmaceuticals Group, completed initial integration, breaking down regional barriers and launching a nationally integrated, highly efficient collaborative system. Meanwhile, China Resources Pharmaceutical Commercial Group successively acquired 51% equity stakes in Anhui Lifang Pharmaceutical and Sichuan Kelun Pharmaceutical Trade Group, thereby enhancing comprehensive competitiveness and market share in the respective regions.

In early 2024, the State-owned Assets Supervision and Administration Commission (SASAC) also proposed incorporating market capitalization management into the performance evaluation system for centrally controlled state-owned enterprises listed on stock exchanges. Driven by policy, mergers and acquisitions in the pharmaceutical distribution sector continued, further increasing the concentration among industry leaders.

Although Shanghai Pharma Group is known as the “leading enterprise in Shanghai,” it still lags behind in retail terminal density in northern China. This acquisition demonstrates that Shanghai Pharma Group is rapidly catching up through capital operations and establishing its own differentiated competitive advantages.

One of Shanghai Pharmaceuticals Group’s distinctive advantages lies in its upstream pharmaceutical manufacturing operations, creating a differentiated “integrated industry and commerce” model. According to SDIC Securities, SPH’s innovative drug pipeline is entering a harvest phase this year. The company also owns several well-known traditional Chinese medicine (TCM) brands, as well as prominent industrial brands such as Sine, Leishi, and Hu Qing Yu Tang. This “new drugs + specialty TCM” portfolio is expected to significantly empower its pharmaceutical manufacturing segment.

Leveraging SPH Health Commerce’s digital capabilities, the holding of Beijing Xinhai Keyuan Pharmacy enables the introduction of these differentiated competencies into the Beijing market, thereby avoiding homogeneous competition.

Of course, the gap between strategic vision and practical execution cannot be ruled out. Whether SPH Health Commerce can successfully replicate its Shanghai experience in Beijing and stand out in the fierce market competition remains to be tested by time. At the very least, this move has been made, and the north-south landscape of China’s pharmaceutical giants has introduced new variables due to this transaction. The full value of this acquisition will only be realized when Shanghai Pharma Group’s innovative drug pipeline achieves true synergy with its self-built commercial network and digital platform.